Mechanism-based inhibition of recombinant human cytochrome P450 3A4 by tomato juice extract

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 3, 2012, Pages 329-334

  Sunaga, Katsuyoshi ^a   Ohkawa, Kenichi ^a   Nakamura, Kenichi ^a   Ohkubo, Atsuko ^a   Harada, Sonoko ^a,b   Tsuda, Tadashi ^a  

^a JOSAI UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Food drug interaction; Human recombinant cytochrome P450 3A4; Mechanism based inhibition; Tomato juice

Indexed keywords

CYTOCHROME P450 3A4; LYCOPENE; MIDAZOLAM; NIFEDIPINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TESTOSTERONE;

\TOMATO JUICE; ARTICLE; AUBERGINE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME INHIBITION; FOOD DRUG INTERACTION; FRUIT JUICE; GRAPEFRUIT JUICE; INCUBATION TIME; PEPPER; PHYTOCHEMISTRY; POTATO; SOLVENT EXTRACTION; SWEET PEPPER; TOMATO; TOMATO JUICE;

ACETATES; BEVERAGES; CYTOCHROME P-450 CYP3A; HUMANS; NADP; PLANT EXTRACTS; RECOMBINANT PROTEINS; SOLANACEAE; SOLVENTS; STEROID HYDROXYLASES; ULTRAFILTRATION;

EID: 84857842546     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.329     Document Type: Article

References (44)

1. Boullata JI. Handbook of drug-nutrient interactions (Boullata JI, Armenti VT ed.), Humana Press, New York, pp. 3-26 (2010).
2. Spence JD. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin. Pharmacol. Ther., 61, 395-400 (1997).
3. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin. Pharmacol. Ther., 68, 28-34 (2000).
4. Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology, 62, 670 (2004).
5. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine, 10, 334-342 (2003).
6. Sand PG, Dreiseitel A, Stang M, Schreier P, Oehme A, Locher S, Hajak G. Cytochrome P450 2C19 inhibitory activity of common berry constituents. Phytother. Res., 24, 304-307 (2010).
7. Kimura Y, Ito H, Hatano T. Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol. Pharm. Bull., 33, 1977-1982 (2010).
8. Fujita T, Kawase A, Niwa T, Tomohiro N, Masuda M, Matsuda H, Iwaki M. Comparative evaluation of 12 immature citrus fruit extracts for the inhibition of cytochrome P450 isoform activities. Biol. Pharm. Bull., 31, 925-930 (2008).
9. MacDonald L, Foster BC, Akhtar H. Food and therapeutic product interactions - a therapeutic perspective. J. Pharm. Pharm. Sci., 12, 367-377 (2009).
10. Hidaka M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab. Dispos., 32, 581-583 (2004).
11. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions. Adv. Pharmacol., 43, 7-35 (1997).
12. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270, 414-423 (1994).
13. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J. Pharmacol. Exp. Ther., 283, 1552-1562 (1997).
14. Paine MF, Oberlies NH. Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions. Expert Opin. Drug Metab. Toxicol., 3, 67-80 (2007).
15. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest., 99, 2545-2553 (1997).
16. Mertens-Talcott SU, Zadezensky I, De Castro WV, Derendorf H, Butterweck V. Grapefruit-drug interactions: can interactions with drugs be avoided? J. Clin. Pharmacol., 46, 1390-1416 (2006).
17. Zhou SF. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4. Curr. Pharm. Des., 14, 990-1000 (2008).
18. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch. Biochem. Biophys., 378, 356-363 (2000).
19. Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. Drug Metab. Pharmacokinet., 20, 34-45 (2005).
20. Usia T, Watabe T, Kadota S, Tezuka Y. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci., 76, 2381-2391 (2005).
21. Usia T, Watabe T, Kadota S, Tezuka Y. Mechanism-based inhibition of CYP3A4 by constituents of Zingiber aromaticum. Biol. Pharm. Bull., 28, 495-499 (2005).
22. Subehan, Zaidi SF, Kadota S, Tezuka Y. Inhibition on human liver cytochrome P450 3A4 by constituents of fennel (Foeniculum vulgare): identification and characterization of a mechanism-based inactivator. J. Agric. Food Chem., 55, 10162-10167 (2007).
23. Taesotikul T, Dumrongsakulchai W, Wattanachai N, Navinpipat V, Somanabandhu A, Tassaneeyakul W, Tassaneeyakul W. Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metab. Pharmacokinet., 26, 154-161 (2011).
24. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet, 337, 268-269 (1991).
25. Tassaneeyakul W, Vannaprasaht S, Yamazoe Y. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br. J. Clin. Pharmacol., 49, 139-144 (2000).
26. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther., 57, 485-491 (1995).
27. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst., 94, 391-398 (2002).
28. Etminan M, Takkouche B, Caamaño-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol. Biomarkers Prev., 13, 340-345 (2004).
29. Sharoni Y, Danilenko M, Dubi N, Ben-Dor A, Levy J. Carotenoids and transcription. Arch. Biochem. Biophys., 430, 89-96 (2004).
30. Wertz K, Siler U, Goralczyk R. Lycopene: modes of action to promote prostate health. Arch. Biochem. Biophys., 430, 127-134 (2004).
31. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol., 48, 716-727 (1999).
32. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos., 28, 360-366 (2000).
33. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther., 302, 645-650 (2002).
34. Kim H, Yoon YJ, Shon JH, Cha IJ, Shin JG, Liu KH. Inhibitory effects of fruit juices on CYP3A activity. Drug Metab. Dispos., 34, 521-523 (2006).
35. Racha JK, Zhao ZS, Olejnik N, Warner N, Chan R, Moore D, Satoh H. Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab. Pharmacokinet., 18, 128-138 (2003).
36. Galetin A, Clarke SE, Houston JB. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab. Dispos., 31, 1108-1116 (2003).
37. Hao M, Zhao Y, Chen P, Huang H, Liu H, Jiang H, Zhang R, Wang H. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS ONE, 3, e2697 (2008).
38. von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Pharmacol., 56, 1039-1044 (2004).
39. Ho PC, Saville DJ, Wanwimolruk S. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm. Pharm. Sci., 4, 217-227 (2001).
40. Quintieri L, Palatini P, Nassi A, Ruzza P, Floreani M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem. Pharmacol., 75, 1426-1437 (2008).
41. Tan HL, Thomas-Ahner JM, Grainger EM, Wan L, Francis DM, Schwartz SJ, Erdman JW Jr, Clinton SK. Tomato-based food products for prostate cancer prevention: what have we learned? Cancer Metastasis Rev., 29, 553-568 (2010).
42. Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos., 25, 1228-1233 (1997).
43. Bailey DG, Arnold JM, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther., 53, 637-642 (1993).
44. Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br. J. Clin. Pharmacol., 36, 460-463 (1993).